Matthew W. Foehr - 04 Aug 2021 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
President and COO
Signature
By: Charles S. Berkman For: Matthew W. Foehr
Issuer symbol
LGND
Transactions as of
04 Aug 2021
Net transactions value
-$677,762
Form type
4
Filing time
05 Aug 2021, 16:44:36 UTC
Previous filing
10 Jun 2021
Next filing
12 Nov 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Options Exercise $193,773 +8,840 +5.4% $21.92 173,195 04 Aug 2021 Direct
transaction LGND Common Stock Sale $969,507 -8,840 -5.1% $109.67 164,355 04 Aug 2021 Direct F1
transaction LGND Common Stock Options Exercise $97,972 +1,142 +0.69% $85.79 165,497 04 Aug 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LGND Employee Stock Option (right to buy) Options Exercise $0 -8,840 -44% $0.000000 11,160 04 Aug 2021 Common Stock 8,840 $21.92 Direct F2
transaction LGND Employee Stock Option (right to buy) Options Exercise $0 -1,142 -4.2% $0.000000 25,938 04 Aug 2021 Common Stock 1,142 $85.79 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.06 to $111.00, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2 Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/15/13.
F3 Grant to reporting person of options to purchase shares of common stock ("Option Shares"), exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/11/16.